Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b
Journal of Clinical Virology, 06/29/2012
Clinical Article
Vispo E et al. – The rate of SVR to pegIFN/RBV therapy tends to be lower in HIV–infected patients with chronic hepatitis C due to HCV–1a than HCV–1b; being the impact of IL28B variants significantly stronger on HCV–1a than HCV–1b.



